<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Molecular Partners Ag — News on 6ix</title>
<link>https://6ix.com/company/molecular-partners-ag</link>
<description>Latest news and press releases for Molecular Partners Ag on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 26 May 2026 20:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/molecular-partners-ag" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68361cf078dffbe2df13fc6a.webp</url>
<title>Molecular Partners Ag</title>
<link>https://6ix.com/company/molecular-partners-ag</link>
</image>
<item>
<title>Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-to-present-at-td-cowens-7th-annual-oncology-innovation-summit</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-to-present-at-td-cowens-7th-annual-oncology-innovation-summit</guid>
<pubDate>Tue, 26 May 2026 20:00:00 GMT</pubDate>
<description>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in the following upcoming investor conference. TD Cowen’s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Fireside chat on Wedn</description>
</item>
<item>
<title>Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-reports-financial-results-and-highlights-for-q1-2026-with-clinical-studies-initiated-on-mp0712-and-mp0317</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-reports-financial-results-and-highlights-for-q1-2026-with-clinical-studies-initiated-on-mp0712-and-mp0317</guid>
<pubDate>Tue, 12 May 2026 20:00:00 GMT</pubDate>
<description>Lead Radio-DARPin MP0712 progressing in Phase 1/2a trial with multiple clinical sites opening and initial clinical data expected in 2026New data on Radio-DARPins’ amenability to range of therapeutic payloads enable isotope-agnostic strategy for expanding pipeline Strong financial position with cash including short-term time deposits of CHF 79 million (approx. USD 100 million), providing runway until late 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad h</description>
</item>
<item>
<title>Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-to-hold-oral-presentations-on-dll3-targeting-radio-darpin-candidate-mp0712-at-multiple-upcoming-scientific-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-to-hold-oral-presentations-on-dll3-targeting-radio-darpin-candidate-mp0712-at-multiple-upcoming-scientific-conferences</guid>
<pubDate>Mon, 04 May 2026 05:00:00 GMT</pubDate>
<description>ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics, today announced its attendance and presentations on its lead Radio-DARPin candidate MP0712 at upcoming scientific conferences. Details of the events: NIH National Cancer Institute 2026 Small Cell Lung Cancer Consortium Meeting May 6–7, Rockville, MD,</description>
</item>
<item>
<title>Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-publishes-phase-1-mp0317-data-in-nature-cancer-demonstrating-tumor-localized-cd40-activation-and-tumor-microenvironment-remodeling</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-publishes-phase-1-mp0317-data-in-nature-cancer-demonstrating-tumor-localized-cd40-activation-and-tumor-microenvironment-remodeling</guid>
<pubDate>Fri, 01 May 2026 11:00:00 GMT</pubDate>
<description>Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer typesPharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitorsRandomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53</description>
</item>
<item>
<title>Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-switch-darpin-t-cell-engager-mp0632-and-dll3-radio-darpin-mp0712</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-switch-darpin-t-cell-engager-mp0632-and-dll3-radio-darpin-mp0712</guid>
<pubDate>Sun, 19 Apr 2026 16:00:00 GMT</pubDate>
<description>MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic windowMP0712, Radio-DARPin candidate in on-going US Phase 1/2a trial, leverages high affinity to DLL3, half-life extension and DLL3 internalization for high tumor accumulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a</description>
</item>
<item>
<title>Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-announces-all-board-proposals-approved-clare-fisher-elected-as-new-board-member-at-annual-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-announces-all-board-proposals-approved-clare-fisher-elected-as-new-board-member-at-annual-general-meeting</guid>
<pubDate>Tue, 14 Apr 2026 20:00:00 GMT</pubDate>
<description>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that Clare Fisher was elected by shareholders to its Board of Directors at the Annual General Meeting (AGM). The appointment, and all other motions p</description>
</item>
<item>
<title>Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-publishes-invitation-to-annual-general-meeting-2026-and-proposes-clare-fisher-for-election-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-publishes-invitation-to-annual-general-meeting-2026-and-proposes-clare-fisher-for-election-to-its-board-of-directors</guid>
<pubDate>Mon, 23 Mar 2026 13:00:00 GMT</pubDate>
<description>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today published the invitation to the Annual General Meeting 2026 and announced the nomination of Clare Fisher for election as a new member of the Board of Directors (BoD) at the Annual General Meeting. The A</description>
</item>
<item>
<title>Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-new-preclinical-data-highlighting-radio-darpins-amenability-to-multiple-isotopes</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-new-preclinical-data-highlighting-radio-darpins-amenability-to-multiple-isotopes</guid>
<pubDate>Thu, 19 Mar 2026 06:00:00 GMT</pubDate>
<description>Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes 177Lu or 203Pb allows for rapid expansion of pipeline with multiple therapeutic isotopes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it</description>
</item>
<item>
<title>Molecular Partners to Hold Three Poster Presentations at AACR 2026</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-to-hold-three-poster-presentations-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-to-hold-three-poster-presentations-at-aacr-2026</guid>
<pubDate>Tue, 17 Mar 2026 20:30:00 GMT</pubDate>
<description>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present three posters at the American Association for Cancer Research (AACR) 2026 Annual Meeting, taking place April 17-22 in San Diego, California, USA. Details of the presentations a</description>
</item>
<item>
<title>Molecular Partners Reports Highlights and Financial Results for Full Year 2025</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-reports-highlights-and-financial-results-for-full-year-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-reports-highlights-and-financial-results-for-full-year-2025-2</guid>
<pubDate>Thu, 12 Mar 2026 20:00:00 GMT</pubDate>
<description>Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticipated in 2026Second Radio-DARPin MP0726 targeting MSLN progressing towards first-in-human imaging; nomination of new Radio-DARPin candidates anticipated mid-2026Development agreement signed with leading radio-isotope specialist Eckert & Ziegler, enabling proprietary Radio-DARPin candidates with range</description>
</item>
<item>
<title>Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-announces-participation-in-march-investor-conferences-and-upcoming-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-announces-participation-in-march-investor-conferences-and-upcoming-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 06:00:00 GMT</pubDate>
<description>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026. Details</description>
</item>
<item>
<title>Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-signs-development-agreement-with-eckert-and-ziegler-for-targeted-alpha-radiotherapeutics-1</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-signs-development-agreement-with-eckert-and-ziegler-for-targeted-alpha-radiotherapeutics-1</guid>
<pubDate>Thu, 26 Feb 2026 06:00:00 GMT</pubDate>
<description>Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac)ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announc</description>
</item>
<item>
<title>Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-announces-presentation-of-first-imaging-and-dosimetry-data-of-dll3-targeting-radiotherapy-mp0712-in-patients-at-twc-2026</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-announces-presentation-of-first-imaging-and-dosimetry-data-of-dll3-targeting-radiotherapy-mp0712-in-patients-at-twc-2026</guid>
<pubDate>Mon, 02 Feb 2026 06:00:00 GMT</pubDate>
<description>Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN</description>
</item>
<item>
<title>Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-highlights-clinical-development-progress-and-anticipated-milestones-at-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-highlights-clinical-development-progress-and-anticipated-milestones-at-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Sun, 11 Jan 2026 20:00:00 GMT</pubDate>
<description>Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026Phase 2 investigator-initiated trial of MP0317 now open with patient dosing ongoing, exploring MP0317 in combination with standard-of-care for patients with cholangiocarcinomaPhase 1/2a trial of multi-specific T cell engager MP0533 ongoing, update on clinical development p</description>
</item>
<item>
<title>Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-to-present-at-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-to-present-at-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Thu, 18 Dec 2025 06:00:00 GMT</pubDate>
<description>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present the Company’s latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco, CA, USA. Chief Executive</description>
</item>
<item>
<title>Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-forms-scientific-advisory-board-to-accelerate-development-of-targeted-radiotherapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-forms-scientific-advisory-board-to-accelerate-development-of-targeted-radiotherapeutics</guid>
<pubDate>Thu, 11 Dec 2025 12:00:00 GMT</pubDate>
<description>Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein dru</description>
</item>
<item>
<title>Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-updated-data-from-ongoing-phase-12a-trial-of-mp0533-in-aml-at-ash-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-updated-data-from-ongoing-phase-12a-trial-of-mp0533-in-aml-at-ash-annual-meeting</guid>
<pubDate>Sun, 07 Dec 2025 12:00:00 GMT</pubDate>
<description>Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR M</description>
</item>
<item>
<title>Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-new-data-for-dll3-targeting-radiotherapy-mp0712-at-trp-summit-europe-2025-highlighting-initial-human-images-and-mechanism-of-action</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-new-data-for-dll3-targeting-radiotherapy-mp0712-at-trp-summit-europe-2025-highlighting-initial-human-images-and-mechanism-of-action</guid>
<pubDate>Wed, 12 Nov 2025 06:00:00 GMT</pubDate>
<description>Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2026 Molecular Partners to host conference call today, November 12 at 10AM ET (4PM CET) ZURICH-SCHLIEREN,</description>
</item>
<item>
<title>Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-additional-preclinical-proof-of-concept-data-on-logic-gated-cd3-switch-darpin-at-sitc-2025</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-additional-preclinical-proof-of-concept-data-on-logic-gated-cd3-switch-darpin-at-sitc-2025</guid>
<pubDate>Mon, 03 Nov 2025 06:00:00 GMT</pubDate>
<description>Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN and EpCAM Induced significant tumor regression in vivo without causing systemic cytokine release, indicating favorable safety profile ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR</description>
</item>
<item>
<title>Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-to-present-updated-data-from-phase-12a-trial-of-mp0533-in-aml-at-ash-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-to-present-updated-data-from-phase-12a-trial-of-mp0533-in-aml-at-ash-annual-meeting</guid>
<pubDate>Mon, 03 Nov 2025 06:00:00 GMT</pubDate>
<description>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present updated data from a Phase 1/2a trial of MP0533, a novel, multispecific T cell engager for acute myeloid leukemia (AML) patients, in a po</description>
</item>
</channel>
</rss>